82 FR 56028 - Agency Forms Undergoing Paperwork Reduction Act Review

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention

Federal Register Volume 82, Issue 226 (November 27, 2017)

Page Range		56028-56030
FR Document		2017-25495
Federal Register, Volume 82 Issue 226 (Monday, November 27, 2017)
[Federal Register Volume 82, Number 226 (Monday, November 27, 2017)]
[Notices]
[Pages 56028-56030]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-25495]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-18-1190]


Agency Forms Undergoing Paperwork Reduction Act Review

    In accordance with the Paperwork Reduction Act of 1995, the Centers 
for Disease Control and Prevention (CDC) has submitted the information 
collection request titled ZEN Colombia Study: Zika in Pregnant Women 
and Children in Colombia to the Office of Management and Budget (OMB) 
for review and approval. CDC previously published a ``Proposed Data 
Collection Submitted for Public Comment and Recommendations'' notice on 
August 30, 2017 to obtain comments from the public and affected 
agencies. CDC did not receive comments related to the previous notice. 
This notice serves to allow an additional 30 days for public and 
affected agency comments.

[[Page 56029]]

    CDC will accept all comments for this proposed information 
collection project. The Office of Management and Budget is particularly 
interested in comments that:
    (a) Evaluate whether the proposed collection of information is 
necessary for the proper performance of the functions of the agency, 
including whether the information will have practical utility;
    (b) Evaluate the accuracy of the agencies estimate of the burden of 
the proposed collection of information, including the validity of the 
methodology and assumptions used;
    (c) Enhance the quality, utility, and clarity of the information to 
be collected;
    (d) Minimize the burden of the collection of information on those 
who are to respond, including, through the use of appropriate 
automated, electronic, mechanical, or other technological collection 
techniques or other forms of information technology, e.g., permitting 
electronic submission of responses; and
    (e) Assess information collection costs.
    To request additional information on the proposed project or to 
obtain a copy of the information collection plan and instruments, call 
(404) 639-7570 or send an email to [email protected]. Direct written comments 
and/or suggestions regarding the items contained in this notice to the 
Attention: CDC Desk Officer, Office of Management and Budget, 725 17th 
Street NW., Washington, DC 20503 or by fax to (202) 395-5806. Provide 
written comments within 30 days of notice publication.

Proposed Project

    ZEN Colombia Study: Zika in Pregnant Women and Children in Colombia 
(OMB Control Number 0920-1190, expires 07/31/2019)--Revision--National 
Center on Birth Defects and Developmental Disabilities, Centers for 
Disease Control and Prevention (CDC).

Background and Brief Description

    Zika virus (ZIKV) infection is a mosquito-borne flavivirus 
transmitted by Aedes species mosquitoes, and also through sexual and 
mother-to-child transmission; laboratory-acquired infections have also 
been reported. Health officials observed sporadic evidence of human 
ZIKV infection in Africa and Asia prior to 2007, when an outbreak of 
ZIKV caused an estimated 5,000 infections in the State of Yap, 
Federated States of Micronesia. Since then, health officials have found 
evidence of ZIKV in 65 countries and territories, mostly in Central and 
South America. Common symptoms of ZIKV in humans include rash, fever, 
arthralgia, and nonpurulent conjunctivitis. The illness is usually mild 
and self-limited, with symptoms lasting for several days to a week; 
however, based on previous outbreaks, some infections are asymptomatic. 
The prevalence of asymptomatic infection in the current Central and 
South American epidemic is unknown.
    Although the clinical presentation of ZIKV infection is typically 
mild, ZIKV infection in pregnancy can cause microcephaly and related 
brain abnormalities when fetuses are exposed in utero. Other adverse 
pregnancy outcomes related to ZIKV infection remain under study, and 
include pregnancy loss, other major birth defects, arthrogryposis, eye 
abnormalities, and neurologic abnormalities.
    As the spectrum of adverse health outcomes potentially related to 
ZIKV infection continues to grow, large gaps remain in our 
understanding of ZIKV infection in pregnancy. These include the full 
spectrum of adverse health outcomes in pregnant women, fetuses, and 
infants associated with ZIKV infection; the relative contributions of 
sexual transmission and mosquito-borne transmission to occurrence of 
infections in pregnancy; and variability in the risk of adverse fetal 
outcomes by gestational week of maternal infection or symptoms of 
infection. There is an urgency to fill these large gaps in our 
understanding given the rapidity of the epidemic's spread and the 
severe health outcomes associated with ZIKV to date.
    Colombia's Instituto Nacional de Salud (INS) began surveillance for 
ZIKV in 2015, reporting the first autochthonous transmission in October 
2015 in the north of the country. As of December 2016, Colombia has 
reported over 106,000-suspected ZIKV cases, with over 19,000 of them 
among pregnant women. With a causal link established between ZIKV 
infection in pregnancy and microcephaly, there is an urgent need to 
understand: How to prevent ZIKV transmission; the full spectrum of 
adverse maternal, fetal, and infant health outcomes associated with 
ZIKV infection; and risk factors for occurrence of these outcomes. To 
answer these questions, INS and the CDC will follow 5,000 women 
enrolled in the first trimester of pregnancy, their male partners, and 
their infants, in various cities in Colombia where ZIKV transmission is 
currently ongoing.
    The primary study objectives are to: (1) Describe the 
sociodemographic and clinical characteristics of the study population; 
(2) Identify risk factors for ZIKV infection in pregnant women and 
their infants. These include behaviors such as use of mosquito-bite 
prevention measures or condoms, and factors associated with maternal-
to-child transmission; (3) Assess the risk for adverse maternal, fetal, 
and infant outcomes associated with ZIKV infection; (4) Assess 
modifiers of the risk for adverse outcomes among pregnant women and 
their infants following ZIKV infection. This includes investigating 
associations with gestational age at infection, presence of ZIKV 
symptoms, extended viremia, mode of transmission, prior infections or 
immunizations, and co-infections.
    The project aims to enroll approximately 5,000 women, 1,250 male 
partners, 4,500 newborns, and a subset of 900 infants/children. 
Pregnant women will be recruited in the first trimester of pregnancy 
for study enrollment, followed by assessments during pregnancy (every 
other week until 32 weeks gestation and monthly thereafter), and within 
10 days postpartum. At all visits, participants will complete visit-
specific questionnaires. In addition to the questionnaires, at all 
pregnancy and delivery visits, participants will receive Colombian 
national recommended clinical care and provide samples for laboratory 
testing.
    Researchers will recruit male partners around the time of the 
pregnant partners' study enrollment, followed by monthly visits until 
his pregnant partner reaches the third trimester (approximately 27 
weeks gestation). If the male partner contracts ZIKV during this time, 
visits will occur every other week until the partner has two negative 
consecutive tests for ZIKV or the pregnancy ends. At all study visits, 
male partners will complete visit-specific questionnaires and provide 
samples for laboratory testing.
    Researchers will follow all newborns of mothers participating in 
the study every other week from birth to 6 months of age. At all 
visits, infants will receive national recommended clinical care (at 
birth and follow-up visits at 1, 2, 3, and 6 months), provide samples 
for laboratory testing, and mothers will complete study-specific 
questionnaires about infant ZIKV symptoms and developmental milestones. 
During follow-up, infants will also have cranial ultrasounds, their 
head circumference measured, and hearing and vision tests. For mothers 
and their infants and as part of clinical care, researchers will 
abstract relevant information from medical records.
    The revised information collection package includes the following 
changes.

[[Page 56030]]

During the data collection period, researchers will follow a subset of 
900 infants until 2-years of age. A parent of each of these infants 
will answer a questionnaire at 6, 9, 12, 18, and 24 months, as well as 
have other clinical assessments performed to examine developmental 
delays.
    CDC will use study results to guide recommendations made by both 
INS and CDC to prevent ZIKV infection; to improve counseling of 
patients about risks to themselves, their pregnancies, their partners, 
and their infants; and to help agencies prepare to provide services to 
affected children and families. Participation in this study is 
voluntary and there are no costs to participants other than their time.
    The total burden hours are 14,210.

                                        Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
                                                                                                      Average
                                                                     Number of       Number of      burden per
          Type of respondents                   Form name           respondents    responses per   response  (in
                                                                                    respondent        hours)
----------------------------------------------------------------------------------------------------------------
Pregnant Women........................  Pregnant Women                       600               1            5/60
                                         Eligibility
                                         Questionnaire.
                                        Pregnant Women                       500               1           35/60
                                         Enrollment
                                         Questionnaire.
                                        Adult Symptoms                       500              15           10/60
                                         Questionnaire.
                                        Pregnant Women Follow-up             500               8           15/60
                                         Questionnaire.
                                        Infant Symptoms                    2,250              14           10/60
                                         Questionnaire.
                                        Parent-Child Eligibility           1,000               1            5/60
                                         Questionnaire.
                                        Parent-Child Enrollment              900               1           20/60
                                         Questionnaire.
                                        Parent-Child Follow-up               900               4           15/60
                                         Questionnaire.
                                        Ages and Stages                    2,250               2           15/60
                                         Questionnaire: 2 and 6
                                         Month Visits.
                                        Ages and Stages                      900               2           15/60
                                         Questionnaire: 12 and
                                         24 Month Visits.
                                        Bayley Scales of Infant              900               3           30/60
                                         and Toddler Development.
                                        Strengths and                        900               1            5/60
                                         Difficulties
                                         Questionnaire.
                                        Peabody Developmental                900               1           30/60
                                         Motor Scales.
                                        Parenting Stress Index               900               5           10/60
                                         IV.
                                        Center for Epidemiologic             900               5            5/60
                                         Studies Depression
                                         Scale.
                                        Test of Nonverbal                    900               1           20/60
                                         Intelligence.
Male partners.........................  Male Partner Eligibility             150               1            5/60
                                         Questionnaire.
                                        Male Enrollment                      125               1           25/60
                                         Questionnaire.
                                        Adult Symptoms                       125               7           10/60
                                         Questionnaire.
----------------------------------------------------------------------------------------------------------------


Leroy A. Richardson,
Chief, Information Collection Review Office, Office of Scientific 
Integrity, Office of the Associate Director for Science, Office of the 
Director, Centers for Disease Control and Prevention.
[FR Doc. 2017-25495 Filed 11-24-17; 8:45 am]
 BILLING CODE 4163-18-P
56028 Federal Register / Vol. 82, No. 226 / Monday, November 27, 2017 / Notices

4. Minimize the burden of the OMB approval to extend this survey for determining health care work force
collection of information on those who an additional three years. needs, and assessing the health status of
are to respond, including through the The target universe of the NHAMCS is the population.
use of appropriate automated, in-person visits made to emergency Starting 2018, CDC will implement
electronic, mechanical, or other departments (EDs) of non-Federal, short- the ED component of NHAMCS.
technological collection techniques or stay hospitals (hospitals with an average However, between December 2017 and
other forms of information technology, length of stay of less than 30 days) that May 2018, the 2017 survey will run
e.g., permitting electronic submissions have at least six beds for inpatient use, concurrently with the 2018 survey. This
of responses. and with a specialty of general (medical is typical with any data collection cycle:
5. Assess information collection costs. or surgical) or children’s general. It begin in the last month of the
NHAMCS was initiated to preceding year and ends around the
Proposed Project complement the National Ambulatory middle of the following year. For the
Medical Care Survey (NAMCS, OMB 2017 data collection, CDC will collect
National Hospital Ambulatory Control Number 0920–0234, Expiration
Medical Care Survey (NHAMCS) (OMB information on all three settings (ED,
Date 03/31/2019), which provides OPD, and ASL). For this three-year
Control Number 0920–0278, Expiration similar data concerning patient visits to
Date 02/28/2018)—Revision—National request, CDC does not expect
physicians’ offices. NAMCS and
Center for Health Statistics (NCHS), substantive changes or supplements for
NHAMCS are the principal sources of
Centers for Disease Control and the survey.
data on ambulatory care provided in the
Prevention (CDC). United States. Users of NHAMCS data include, but
NHAMCS provides a range of baseline are not limited to, congressional offices,
Background and Brief Description
data on the characteristics of the users Federal agencies, state and local
Section 306 of the Public Health and providers of hospital ambulatory governments, schools of public health,
Service (PHS) Act (42 U.S.C. 242k), as medical care. Data collected include colleges and Universities, private
amended, authorizes that the Secretary patients’ demographic characteristics, industry, nonprofit foundations,
of Health and Human Services (DHHS), reason(s) for visit, providers’ diagnoses, professional associations, clinicians,
acting through NCHS, shall collect diagnostic services, medications, and researchers, administrators, and health
statistics on ‘‘utilization of health care’’ disposition. These data, together with planners.
in the United States. The National trend data, may be used to monitor the There are no costs to the respondents
Hospital Ambulatory Medical Care effects of change in the health care other than their time. The total
Survey (NHAMCS) has conducted system, for the planning of health estimated annualized burden hours are
annually since 1992. NCHS is seeking services, improving medical education, 1,806.

ESTIMATED ANNUALIZED BURDEN HOURS
Average
Number of
Number of burden per Total burden
Type of respondents Form name responses per
respondents response (in hours)
respondent (in hours)

Hospital Chief Executive Officer ....... Hospital Induction 2017 Data Col- 60 1 75/60 75
lection.
Hospital Chief Executive Officer ....... Hospital Induction 2018+ Data Col- 340 1 75/60 425
lection.
Ancillary Service Executive ............... Ambulatory Unit Induction (ED, OPD 810 1 15/60 203
and ASL).
Ancillary Service Executive ............... Ambulatory Unit Induction (ED only) 583 1 15/60 146
Medical Record Clerk ....................... Retrieving Patient Records (ED, 396 144 1/60 950
OPD and ASL).
Ancillary Service Executive—Re- Reabstraction Telephone Call (ED, 29 1 5/60 2
abstraction. OPD and ASL).
Medical Record Clerk—Reabstrac- Pulling and re-filing Patient Records 29 10 1/60 5
tion. (ED, OPD and ASL).

Total ........................................... ........................................................... ........................ ........................ ........................ 1,806

Leroy A. Richardson, DEPARTMENT OF HEALTH AND collection request titled ZEN Colombia
Chief, Information Collection Review Office, HUMAN SERVICES Study: Zika in Pregnant Women and
Office of Scientific Integrity, Office of the Children in Colombia to the Office of
Associate Director for Science, Office of the Centers for Disease Control and Management and Budget (OMB) for
Director, Centers for Disease Control and Prevention review and approval. CDC previously
Prevention.
asabaliauskas on DSKBBXCHB2PROD with NOTICES

published a ‘‘Proposed Data Collection
[FR Doc. 2017–25496 Filed 11–24–17; 8:45 am] [30Day–18–1190] Submitted for Public Comment and
BILLING CODE 4163–18–P
Agency Forms Undergoing Paperwork Recommendations’’ notice on August
Reduction Act Review 30, 2017 to obtain comments from the
public and affected agencies. CDC did
In accordance with the Paperwork not receive comments related to the
Reduction Act of 1995, the Centers for previous notice. This notice serves to
Disease Control and Prevention (CDC) allow an additional 30 days for public
has submitted the information and affected agency comments.

VerDate Sep<11>2014 16:59 Nov 24, 2017 Jkt 244001 PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 E:\FR\FM\27NON1.SGM 27NON1
Federal Register / Vol. 82, No. 226 / Monday, November 27, 2017 / Notices 56029

CDC will accept all comments for this America. Common symptoms of ZIKV ZIKV infection in pregnant women and
proposed information collection project. in humans include rash, fever, their infants. These include behaviors
The Office of Management and Budget arthralgia, and nonpurulent such as use of mosquito-bite prevention
is particularly interested in comments conjunctivitis. The illness is usually measures or condoms, and factors
that: mild and self-limited, with symptoms associated with maternal-to-child
(a) Evaluate whether the proposed lasting for several days to a week; transmission; (3) Assess the risk for
collection of information is necessary however, based on previous outbreaks, adverse maternal, fetal, and infant
for the proper performance of the some infections are asymptomatic. The outcomes associated with ZIKV
functions of the agency, including prevalence of asymptomatic infection in infection; (4) Assess modifiers of the
whether the information will have the current Central and South American risk for adverse outcomes among
practical utility; epidemic is unknown. pregnant women and their infants
(b) Evaluate the accuracy of the Although the clinical presentation of following ZIKV infection. This includes
agencies estimate of the burden of the ZIKV infection is typically mild, ZIKV investigating associations with
proposed collection of information, infection in pregnancy can cause gestational age at infection, presence of
including the validity of the microcephaly and related brain ZIKV symptoms, extended viremia,
methodology and assumptions used; abnormalities when fetuses are exposed mode of transmission, prior infections
(c) Enhance the quality, utility, and in utero. Other adverse pregnancy or immunizations, and co-infections.
clarity of the information to be outcomes related to ZIKV infection The project aims to enroll
collected; remain under study, and include approximately 5,000 women, 1,250 male
(d) Minimize the burden of the pregnancy loss, other major birth partners, 4,500 newborns, and a subset
collection of information on those who defects, arthrogryposis, eye of 900 infants/children. Pregnant
are to respond, including, through the abnormalities, and neurologic women will be recruited in the first
use of appropriate automated, abnormalities. trimester of pregnancy for study
electronic, mechanical, or other As the spectrum of adverse health enrollment, followed by assessments
technological collection techniques or outcomes potentially related to ZIKV during pregnancy (every other week
other forms of information technology, infection continues to grow, large gaps until 32 weeks gestation and monthly
e.g., permitting electronic submission of remain in our understanding of ZIKV thereafter), and within 10 days
responses; and infection in pregnancy. These include postpartum. At all visits, participants
(e) Assess information collection the full spectrum of adverse health will complete visit-specific
costs. outcomes in pregnant women, fetuses, questionnaires. In addition to the
To request additional information on and infants associated with ZIKV questionnaires, at all pregnancy and
the proposed project or to obtain a copy infection; the relative contributions of delivery visits, participants will receive
of the information collection plan and sexual transmission and mosquito-borne Colombian national recommended
instruments, call (404) 639–7570 or transmission to occurrence of infections clinical care and provide samples for
send an email to omb@cdc.gov. Direct in pregnancy; and variability in the risk laboratory testing.
written comments and/or suggestions of adverse fetal outcomes by gestational Researchers will recruit male partners
regarding the items contained in this week of maternal infection or symptoms around the time of the pregnant
notice to the Attention: CDC Desk of infection. There is an urgency to fill partners’ study enrollment, followed by
Officer, Office of Management and these large gaps in our understanding monthly visits until his pregnant
Budget, 725 17th Street NW., given the rapidity of the epidemic’s partner reaches the third trimester
Washington, DC 20503 or by fax to (202) spread and the severe health outcomes (approximately 27 weeks gestation). If
395–5806. Provide written comments associated with ZIKV to date. the male partner contracts ZIKV during
within 30 days of notice publication. Colombia’s Instituto Nacional de this time, visits will occur every other
Salud (INS) began surveillance for ZIKV week until the partner has two negative
Proposed Project in 2015, reporting the first consecutive tests for ZIKV or the
ZEN Colombia Study: Zika in autochthonous transmission in October pregnancy ends. At all study visits, male
Pregnant Women and Children in 2015 in the north of the country. As of partners will complete visit-specific
Colombia (OMB Control Number 0920– December 2016, Colombia has reported questionnaires and provide samples for
1190, expires 07/31/2019)—Revision— over 106,000-suspected ZIKV cases, laboratory testing.
National Center on Birth Defects and with over 19,000 of them among Researchers will follow all newborns
Developmental Disabilities, Centers for pregnant women. With a causal link of mothers participating in the study
Disease Control and Prevention (CDC). established between ZIKV infection in every other week from birth to 6 months
pregnancy and microcephaly, there is an of age. At all visits, infants will receive
Background and Brief Description urgent need to understand: How to national recommended clinical care (at
Zika virus (ZIKV) infection is a prevent ZIKV transmission; the full birth and follow-up visits at 1, 2, 3, and
mosquito-borne flavivirus transmitted spectrum of adverse maternal, fetal, and 6 months), provide samples for
by Aedes species mosquitoes, and also infant health outcomes associated with laboratory testing, and mothers will
through sexual and mother-to-child ZIKV infection; and risk factors for complete study-specific questionnaires
transmission; laboratory-acquired occurrence of these outcomes. To about infant ZIKV symptoms and
infections have also been reported. answer these questions, INS and the developmental milestones. During
asabaliauskas on DSKBBXCHB2PROD with NOTICES

Health officials observed sporadic CDC will follow 5,000 women enrolled follow-up, infants will also have cranial
evidence of human ZIKV infection in in the first trimester of pregnancy, their ultrasounds, their head circumference
Africa and Asia prior to 2007, when an male partners, and their infants, in measured, and hearing and vision tests.
outbreak of ZIKV caused an estimated various cities in Colombia where ZIKV For mothers and their infants and as
5,000 infections in the State of Yap, transmission is currently ongoing. part of clinical care, researchers will
Federated States of Micronesia. Since The primary study objectives are to: abstract relevant information from
then, health officials have found (1) Describe the sociodemographic and medical records.
evidence of ZIKV in 65 countries and clinical characteristics of the study The revised information collection
territories, mostly in Central and South population; (2) Identify risk factors for package includes the following changes.

VerDate Sep<11>2014 16:59 Nov 24, 2017 Jkt 244001 PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 E:\FR\FM\27NON1.SGM 27NON1
56030 Federal Register / Vol. 82, No. 226 / Monday, November 27, 2017 / Notices

During the data collection period, assessments performed to examine their partners, and their infants; and to
researchers will follow a subset of 900 developmental delays. help agencies prepare to provide
infants until 2-years of age. A parent of CDC will use study results to guide services to affected children and
each of these infants will answer a recommendations made by both INS families. Participation in this study is
questionnaire at 6, 9, 12, 18, and 24 and CDC to prevent ZIKV infection; to voluntary and there are no costs to
months, as well as have other clinical improve counseling of patients about participants other than their time.
risks to themselves, their pregnancies, The total burden hours are 14,210.
ESTIMATED ANNUALIZED BURDEN HOURS
Average
Number of
Number of burden per
Type of respondents Form name responses per
respondents response
respondent (in hours)

Pregnant Women ............................................ Pregnant Women Eligibility Questionnaire .... 600 1 5/60
Pregnant Women Enrollment Questionnaire 500 1 35/60
Adult Symptoms Questionnaire ..................... 500 15 10/60
Pregnant Women Follow-up Questionnaire ... 500 8 15/60
Infant Symptoms Questionnaire ..................... 2,250 14 10/60
Parent-Child Eligibility Questionnaire ............. 1,000 1 5/60
Parent-Child Enrollment Questionnaire ......... 900 1 20/60
Parent-Child Follow-up Questionnaire ........... 900 4 15/60
Ages and Stages Questionnaire: 2 and 6 2,250 2 15/60
Month Visits.
Ages and Stages Questionnaire: 12 and 24 900 2 15/60
Month Visits.
Bayley Scales of Infant and Toddler Devel- 900 3 30/60
opment.
Strengths and Difficulties Questionnaire ........ 900 1 5/60
Peabody Developmental Motor Scales .......... 900 1 30/60
Parenting Stress Index IV .............................. 900 5 10/60
Center for Epidemiologic Studies Depression 900 5 5/60
Scale.
Test of Nonverbal Intelligence ....................... 900 1 20/60
Male partners .................................................. Male Partner Eligibility Questionnaire ............ 150 1 5/60
Male Enrollment Questionnaire ...................... 125 1 25/60
Adult Symptoms Questionnaire ..................... 125 7 10/60

Leroy A. Richardson, Description: The Family and Youth Performance Analysis Study, and an
Chief, Information Collection Review Office, Services Bureau (FYSB) and the Office Impact and In-Depth Implementation
Office of Scientific Integrity, Office of the of Planning, Research, Evaluation Study. Data collection related to the
Associate Director for Science, Office of the (OPRE) in the Administration for Design and Implementation Study is
Director, Centers for Disease Control and Children and Families (ACF) are complete; data collection related to the
Prevention. requesting an extension without change Performance Analysis Study will be
[FR Doc. 2017–25495 Filed 11–24–17; 8:45 am] of a currently approved information complete in late summer 2017. This
BILLING CODE 4163–18–P collection (OMB No. 0970–0398). The notice is specific to data collection
purpose of the extension is to complete activities for the Impact and In-Depth
the ongoing follow-up data collection Implementation Study, which is being
DEPARTMENT OF HEALTH AND for the Personal Responsibility conducted in four sites. The proposed
HUMAN SERVICES Education Program (PREP) Multi- extension is necessary to complete
Administration for Children and Component Evaluation, which was ongoing follow-up data collection. The
Families designed to document how PREP resulting data will be used in a rigorous
programs are designed and program impact analysis to assess the
Submission for OMB Review; implemented in the field, collect effectiveness of each program in
Comment Request performance measure data for PREP reducing teen sexual activity and
programs, and assess the effectiveness of associated risk behaviors.
Title: Personal Responsibility selected PREP-funded programs. Respondents: Youth participants who
Education Program (PREP) Multi- The PREP Multi-Component agreed to participate in the study upon
Component Evaluation Extension. Evaluation contains three components: enrollment in the four impact study
OMB No.: 0970–0398. A Design and Implementation Study, a sites.
asabaliauskas on DSKBBXCHB2PROD with NOTICES

ANNUAL BURDEN ESTIMATES
Total/annual Number of Average Total/annual
Instrument number of responses per burden hours burden hours
respondents respondents per response

Second follow-up survey ................................................................................. 325 1 .75 244

VerDate Sep<11>2014 16:59 Nov 24, 2017 Jkt 244001 PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\27NON1.SGM 27NON1
Document Created: 2017-11-25 01:08:41
Document Modified: 2017-11-25 01:08:41
Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
FR Citation		82 FR 56028
82 FR 56028 - Agency Forms Undergoing Paperwork Reduction Act Review

DEPARTMENT OF HEALTH AND HUMAN SERVICESCenters for Disease Control and Prevention

Federal Register Volume 82, Issue 226 (November 27, 2017)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
